INTRODUCTION AND OBJECTIVES: Prostate cancer (Pca) bone metastases are characterized by abnormal bone remodeling processes and result in the release of components from the osseous metabolism into the blood stream. The objective of this study was to detect the components alteration in serum using Surface-Enhanced Raman Spectroscopy (SERS) and then evaluated the performance of Raman spectra in diagnosis of bone metastases.
INTRODUCTION AND OBJECTIVES: Prostate cancer (Pca) bone metastases are characterized by abnormal bone remodeling processes and result in the release of components from the osseous metabolism into the blood stream. The objective of this study was to detect the components alteration in serum using Surface-Enhanced Raman Spectroscopy (SERS) and then evaluated the performance of Raman spectra in diagnosis of bone metastases.
METHODS: We analyzed serum samples from Pca patients with and without bone metastases using Surface-Enhanced Raman Spectroscopy (SERS) technology. The Principal component analysis was used to extract the signature of Raman spectra and The linear discriminate analysis was used to develop diagnostic algorithm.
RESULTS: A total of 336 Raman spectra of serum were collected from 112 patients, and were compared between Pca patients developed bone metastases and patients had locally confined cancer. The SERS detected more abundant C-N stretching vibration rich proteins, Lipids and CH vibration rich DNA/RNA bases in bloodstream of metastasized patients. The leave-one-out cross-validation method was used to validate the PCA-LDA model and revealed the sensitivity and specificity of 73.8% and 86.2% respectively. The receiver operating characteristic (ROC) curve was used to evaluate the performance diagnostic model, area under the ROC curve was 0.89. CONCLUSIONS: Our results revealed the Raman spectral signature of serum from bone metastasized patients. The PCA-LDA analysis of Raman spectra suggested that SERS could be meaningful technique for prostate cancer bone metastases screening.
Source of Funding: none

MP18-03 THE CHINESE ANTI-CANCER ASSOCIATION GENITOURINARY CANCER COMMITTEE PROSTATE CANCER SCREENING PROGRAM: A PRELIMINARY REPORT AFTER RECRUITMENT OF 2162 MEN
Yongqiang Huang*, Chengyuan Gu, Xiaojian Qin, Yuanyuan Qu, Jianfeng Yang, Jing Hong, li Liu, Kefa Zheng, Lihua Xu, Huaiping Zhao, Xiongxion Qian, Dingwei Ye, Shanghai, China, People's Republic of INTRODUCTION AND OBJECTIVES: There is marked regional differences in the prostate cancer (PCa) incidence and mortality rates rate between China and the West. The incidence of PCa is increasing rapidly in China, the clinical stage of PCa patients is comparatively late and the overall survival rate is inferior to that reported in the developed countries. Though population-based PSA screening still is controversially discussed in the West, it is an effective measure to reduce the risk of death through early detection. The Chinese Anti-Cancer Association Genitourinary Cancer Committee Prostate Cancer Screening Program is currently the largest ongoing screening program in China and aims to accrue 50,000 men within 5 yrs in a prospective fashion. The program started in June 2017.
METHODS: According to Chinese consensus of prostate cancer screening, eligible men aged 50 with life expectancy over 10 years or aged 45 with high risk (e.g. those with a first degree relative diagnosed with PCa; age >40 yrs with baseline PSA ! 1.0 mg/ml). The interviewer-administered questionnaire covered demographic characteristics and environmental exposure factors. Prostate-specific antigen (PSA) determination in serum with a cut-off of !4.0 ng/ml was the main screening test and indication for biopsy. The FRENDTM System is employed for a precise and rapid PSA detection. The Institutional Review Board of Fudan University Shanghai Cancer Center approved this study, and a written informed consent was obtained from all recruited individuals.
RESULTS: 2, 162 men have been enrolled until October 2018. The median age was 70.0 yrs (45-85). Median PSA of theses participants was 1.21 ng/ml (range 0.01-25.0). Altogether, 11.0% (237 cases) had a confirmed PSA increase ! 4.0 ng/ml (median 9.1, range 4.0-25.0). Subsequently, 58 subjects (24.5%) out of the 237 PSAsuspicious men underwent prostate biopsy, and 38 were confirmed as PCa. Until now, the overall PCa incidence in the first screening round is 1.76%. We evaluated the associations between demographic, environmental exposure factors and PCa risk. Age (OR: 2.63; 95% CI: 1.84-3.75, P <0.001), sleep hours (OR: 1.88; 95% CI: 1.37-2.58, P <0.001) and chronic prostatitis history (OR: 2.02; 95% CI: 1.55-2.63, P <0.001) were significantly associated with PSA level. After adjustment for these factors, older age (OR: 4.04; 95% CI: 1.71-9.59, P [ 0.002) and no statins use (OR: 3.09; 95% CI: 1.25-7.69, P [0.015) were associated with an elevated risk of PCa.
CONCLUSIONS: Although largely underestimated, the incidence of PCa in the targeted Chinese population is higher than expected. Older men have a high risk of harboring PCa. Our study suggests a decreased risk of PCa in men with statins use.
Source of Funding: None
MP18-04 IMPACT OF PUTATIVE CHEMOPREVENTATIVE AGENTS ON PROSTATE CANCER DIAGNOSIS
INTRODUCTION AND OBJECTIVES: Prostate cancer (PC) is the most common non-cutaneous cancer in Canadian men and the third most common cause of cancer death in males accounting for 10% of all male cancer deaths in Canada. Several observational and randomized studies have shown that use of commonly prescribed medications, including those used for the treatment of diabetes and hypercholesterolemia, is associated with improved survival in various malignancies, including PC. There has not been any large populationbased study, examining the effects of these and other commonly prescribed medications, such as proton pump inhibitors (PPI), on the rate of PC diagnosis, over more than 20 years of follow-up.
METHODS: A retrospective population-based study using data from the Institute of clinical evaluative sciences (ICES), including all male patients aged 65 and above in Ontario who have had a negative first prostate biopsy between 1994 and 2016. We assessed the impact of commonly prescribed medications on PC diagnosis.
